Feedback
Settings

Settings

Goto Application

1. WO2021075544 - RI-LABELED HUMANIZED ANTIBODY

PermaLink
Publication Number WO/2021/075544
Publication Date 22.04.2021
International Application No. PCT/JP2020/039074
International Filing Date 16.10.2020
IPC
A61K 51/10 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
08Peptides, e.g. proteins
10Antibodies or immunoglobulins; Fragments thereof
A61K 47/68 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/18 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C12N 15/13 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
CPC
A61K 39/39591
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39591Stabilisation, fragmentation
A61K 51/0482
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
0474complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
0482chelates from cyclic ligands, e.g. DOTA
A61K 51/1027
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
1027against receptors, cell-surface antigens or cell-surface determinants
A61K 51/1045
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
1045against animal or human tumor cells or tumor cell determinants
A61K 51/1093
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
1093conjugates with carriers being antibodies
A61K 51/1096
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
1093conjugates with carriers being antibodies
1096radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
Applicants
  • 日本メジフィジックス株式会社 NIHON MEDI-PHYSICS CO., LTD. [JP]/[JP]
  • 住友ファーマ株式会社 SUMITOMO PHARMA CO., LTD. [JP]/[JP]
Inventors
  • 中田　徳仁 NAKATA, Norihito
  • 小橋　信弥 KOBASHI, Nobuya
  • 正山　祥生 SHOYAMA, Yoshinari
  • 的野　光洋 MATONO, Mitsuhiro
  • 落合　康 OCHIAI, Yasushi
  • 村上　貴之 MURAKAMI, Takayuki
Agents
  • 高島　一 TAKASHIMA, Hajime
Priority Data
2019-19156218.10.2019JP
Publication Language Japanese (ja)
Filing Language Japanese (JA)
Designated States
Title
(EN) RI-LABELED HUMANIZED ANTIBODY
(FR) ANTICORPS HUMANISÉ MARQUÉ PAR RI
(JA) ＲＩ標識されたヒト化抗体
front page image
Abstract
(EN) This RI-labeled anti-MUC5AC humanized antibody is a complex of a radionuclide-chelated chelating agent and an antibody (the radionuclide is a metal nuclide that emits α-rays or positrons, and the antibody is a humanized antibody that binds specifically to MUC5AC) and is very useful in the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, especially cancer, due to excellent specificity for MUC5AC and ability to accumulate in tumors.
(FR) Le présent anticorps humanisé anti-MUC5AC marqué par RI est un complexe d'un agent chélatant chélaté par un radionucléide et un anticorps (le radionucléide est un nucléide métallique qui émet des rayons alpha ou des positrons, et l'anticorps est un anticorps humanisé qui se lie spécifiquement à MUC5AC) et est très utile dans le traitement et/ou le diagnostic de maladies dans lesquelles le MUC5AC est surexprimé, en particulier le cancer, en raison d'une excellente spécificité pour MUC5AC et de la capacité à s'accumuler dans des tumeurs.
(JA) 本発明のＲＩ標識された抗ＭＵＣ５ＡＣヒト化抗体は、放射性核種がキレートしたキレート剤と、抗体との複合体（前記放射性核種がα線又はポジトロンを放出する金属核種であり、前記抗体が、ＭＵＣ５ＡＣに特異的に結合するヒト化抗体である）であり、ＭＵＣ５ＡＣに対する特異性と腫瘍への集積性に優れているので、ＭＵＣ５ＡＣが過剰発現している疾患、特にがんの治療及び／又は診断に極めて有用である。
Related patent documents
JPWO2021075544
AU2020367415
SG11202203860W
CN114585393
CA3158322
KR1020220084135
BR112022007313
MYPI 2022001952
EA202291181
EP4049684
US20210338852
JP2022088398
IL292133
TH2201002187This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
PH12022550894This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
MXMX/a/2022/004582This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
BR112022007313This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
NZ787816
IN202247027624
Latest bibliographic data on file with the International Bureau
# -